이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

Handok, Sobi to collaborate on rare disease treatment

Collected: 2024.02.14

Distributed: 2024.02.15

Source: Go Direct

[Courtesy of Handok, Sobi]

South Korean pharmaceutical company Handok Inc. will form a joint venture with Swedish biopharmaceutical company Swedish Orphan Biovitrum AB (Sobi), in a move aimed at enhancing its competitiveness in rare disease treatment.

Handok said on Tuesday that it decided to establish a joint venture with Sobi for rare disease business via a board resolution that was decided on during the previous week. The Korean drugmaker and Sobi plan to establish a joint venture in the first half of 2024 and introduce Sobi’s rare disease treatments to the Korean market.

Sobi is a global biopharmaceutical company that specializes in rare diseases and produces innovative therapies in the hematology and immunology fields. Its main products include Empaveli, a treatment for adult patients with paroxysmal nocturnal hemoglobinuria, and Doptelet, a treatment for adult patients with chronic immune thrombocytopenia.

Handok signed a strategic partnership with Sobi in October 2023 and is currently working towards domestic approvals for Empaveli and Doptelet as part of the duo’s first collaboration. “We eagerly anticipate our collaboration with Handok to introduce innovative therapies in Korea, beginning with Empaveli and Doptelet,” Sobi Chief Executive Officer Guido Oelkers said.

Handok has been introducing innovative medicines in Korea via its extensive collaboration with global companies. It is the Korean supplier for Galafold, the first and only oral therapy for adults with Fabry disease developed by Amicus Therapeutics Inc., as well as hepatic veno-occlusive disease treatment Defitelio and acute myeloid leukemia treatment Vyxeos from Jazz Pharmaceuticals Plc.

By Kang Min-ho and Chang Iou-chung

List

Previous: Eugene ENT gains YTN shareholder rights

Next: LG Uplus offers quick USIM delivery service for thrifty phone buyers